Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Chrystal M. Paulos
Emory University
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
35
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
A Phase Ib/Ii Trial of Xl888 (Hsp90 Inhibitor) and Pembrolizumab in Metastatic Pancreatic Cancer with Translational Immune Profiling
Number of pages: 51
Posted: 06 Aug 2025
NATALIE HORVAT
,
Maria Diab
,
Maggie J. Phillips
,
Ashley Veal-McCook
,
Olatunji B. Alese
,
Emily Greene
,
Olumide Gbolahan
,
Kathleen Coleman
,
Deon Doxie
,
Cameron J. Herting
,
Jacklyn Hammons
,
Zaid Mahdi
,
Jeffrey M. Switchenko
, Chrystal M. Paulos,
Bassel F. El-Rayes
and
Gregory B. Lesinski
Emory University, Henry Ford Health System - Henry Ford Hospital, Emory University,
affiliation not provided to SSRN
, Emory University - Department of Hematology and Medical Oncology, Emory University, Emory University, Emory University,
affiliation not provided to SSRN
, Emory University, Emory University, Emory University - Emory University Hospital, Emory University, Emory University, University of Alabama at Birmingham and Emory University
Downloads
35
(1,263,436)
View PDF
Download
Abstract:
PDAC, checkpoint inhibition, HSP90 inhibition, Liver metastasis, Immunotherapy resistance
Feedback